Compare Crispr Therapeutics AG (CRSP) vs Indonesia Energy Corporation Limited (INDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Indonesia Energy Corporation Limited — how do they compare? Crispr Therapeutics AG trades at $50.61 (market cap $4.97B), while Indonesia Energy Corporation Limited trades at $2.94 (market cap $45.24M). The key difference: Crispr Therapeutics AG is far larger — about 109.9× Indonesia Energy Corporation Limited's market cap. Which is the better fit depends on your goals.
| CRSP | INDO | |
|---|---|---|
Market Cap | $4.97B | $45.24M |
Sector | Health | Energy |
52-Week High | $76.78 | $6.74 |
52-Week Low | $44.34 | $2.49 |
Enterprise Value | $3.32B | $40.61M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
INDO trades at $3.00, up 9.49% today, with a bullish technical signal from moving averages and oscillators. The company reported a net loss of $5 million on $2 million revenue in 2025, with negative profit margins. Recent news highlights operational progress, including the commencement of drilling at the Kruh Block. Analyst consensus is unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of new well operations to drive revenue growth and reduce losses. Key risks include sustained negative profitability and operational challenges in oil exploration. Upside potential exists if production targets are met, but investors face significant financial and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →
